Rezaie explains how IBS care has shifted from symptom-based treatment to targeted, mechanism-driven strategies.
Ali Rezaie, MD
Advertisement
Ali Rezaie, MD, is medical director of the GI Motility Program at Cedars-Sinai.
Articles by Ali Rezaie, MD
New long-term data link antidepressant use in IBS to higher mortality risk. Rezaie explains key findings and clinical implications.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5